The Latest Cardiac and Vascular News
VANCOUVER and MAINZ, Germany, Nov. 12, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a […]
Data Published in JACC: Clinical Electrophysiology and to be Presented at American Heart Association Scientific Sessions Demonstrates the Potential of Investigational Algorithms in Medtronic Micra Pacemaker to Improve Synchrony and Cardiac Function in AV Block Patients DUBLIN, Nov. 11, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced results from the MARVEL […]
Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo Data Support Advancement of Mavacamten in Non-obstructive HCM; Regulatory Update Anticipated in the First Half of 2020 Phase 2 Study of Mavacamten Targeting […]
Prespecified Analysis of 3,146 Patients in the USA Enrolled in REDUCE-IT Showed 31% Relative Risk Reductions for First Occurrence of Both 5-Point MACE and 3-Point MACE Significant Reductions Shown in All Predefined Composite and Individual Cardiovascular Endpoints, Including Cardiovascular Death and All-Cause Mortality Tolerability and Safety Findings Consistent with Full […]
Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s Favorable Impact on Cardiac Structure Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT); Data Presentation at American Heart Association Scientific Sessions on Monday, […]
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF). The data showed that FARXIGA on top of standard of care reduced the incidence of the primary composite endpoint of cardiovascular (CV) death or worsening of HF […]
Recent Highlights · Delivered continued revenue growth for Neovasc ReducerTM (“Reducer”) · Reducer added to the European Society of Cardiology Practice Guidelines for the treatment of refractory angina · Reducer featured at the 40th Annual National Congress of the Italian Society of Interventional Cardiology · Announced Norman Radow joined the board of directors · Granted a […]
ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation technologies. VIVO uses information commonly collected prior to cardiac procedures to identify […]
Company on track for sNDA submission to the FDA by year-end SPARTA, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and […]
SANTA CLARA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2019. Recent Highlights Recognized revenue of $11.3 million […]
